Axceler8 Rx: AI Precision for Clinical Trial Acceleration
A next-generation analytics platform built by Arthur D. Little & Vega IT, delivering measurable speed, accuracy, and control across clinical development.
Already used by leading pharma study teams to accelerate feasibility, startup, and enrollment.
Voices from the frontlines of clinical trials
Strong work. I’m truly impressed by the collaboration and input from so many contributors to bring this together. Reviewing the results put a huge smile on my face this morning!
Thank you for this view that places all scenarios into one simple, easy-to-digest view. This will be extremely helpful for upcoming strategic discussions with senior leadership to determine the optimal study footprint and understand tradeoffs.
The additional site selection list helped us mitigate the high volume of declines during SFQ with our original list, as we pushed toward adding ~100 more sites.
Many thanks for the efficient turnaround with these targeted analyses. The message was clear — even with a 30% faster activation rate, overall last-patient-in barely moves. That clarity has helped our leadership focus on the right levers.”
Very useful information on the deep-dive rationale for site and country-specific rating in Portugal, as we consider additional high-potential countries in Europe. Thank you very much.
Thank you for the close collaboration over the past weeks to deliver semi-bottom-up projections for the critical lymphoma study.
Quantified, Proven Acceleration
End-to-end Unified Acceleration Intelligence
Axceler8 Rx uses real-world trial data, AI analytics, and operational expertise from Arthur D. Little in a connected command center developed by Vega IT for clinical trial acceleration.
It replaces static spreadsheets and fragmented trackers with predictive tools that show, in real time, how to reach milestones faster.
Supporting smarter, more predictable clinical trials
Planning Face
AI Site Selection
When a pharma company prepares to launch a new clinical trial, one of the first and most complex decisions is where the study can realistically succeed. Selecting sites based on intuition or limited feasibility data often leads to overambitious plans, slow start-up, and enrolment delays.
The AI Site Selection module addresses this challenge by analysing historical clinical trial data for the same or similar indications. It identifies comparable past studies, extracts the sites that previously participated, and presents them as a pool of potential candidates for the new trial.
Enrolment Forecast
The core problem the Enrolment Forecast module addresses is providing a realistic projection of how a clinical trial is likely to progress and what outcomes can be expected over time.
During trial planning, it works with limited inputs such as indication, early feasibility assumptions, and historical experience from similar studies. Based on this data, it generates projected enrolment curves that help teams test assumptions and understand how different site, country, or criteria configurations may affect timelines.
Monitoring Face
Site Navigator
The Site Navigator module provides study teams with a clear, structured view of every step required to activate a site, from initial readiness through ongoing performance. Each activity is tracked as part of a broader activation flow, making it easy to see where progress is slowing down.
It helps teams quickly identify where delays are occurring, whether at country level, site level, or within specific tasks.
Trial Dashboard Suite
Trial Dashboard Suite supports ongoing trial monitoring by tracking enrolment progress, data collection status, and compliance milestones across sites and countries. Study teams can compare actual enrolment against forecasts, identify deviations early, and adjust recruitment strategies as trials progress.
By consolidating information at program, study, site, country, and participant level, it provides a consistent overview of trial performance while still allowing teams to drill into specific areas when needed.
Data Speak
Make smarter decisions before your trial begins
Tap into verified global clinical trial data to explore and compare countries and sites that fit your study’s needs. Use the enrolment simulator to project timelines and recruitment outcomes based on your setup - all before enrolling a single patient. Plan with confidence, backed by real-world data.
About the team
Axceler8 Rx is developed and delivered by Arthur D. Little, the world’s first management consultancy and a recognized leader in clinical-trial acceleration together with Vega IT - a digital product development and system integration company with global experience in delivering innovative digital solutions in the healthcare industry in more than 25 countries.
Our team includes clinical operations veterans, data scientists, and AI engineers who have delivered measurable acceleration across oncology, neurology, immunology, cardiology, and rare disease studies.
Bring Predictive Intelligence to Your Next Study
Discover how Axceler8 Rx can transform feasibility, forecasting, and execution with proven analytics and expert support.
